المؤلفون: Thomas SE; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands. sarah.thomas@radboudumc.nl., Seyger MMB; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands., Mangnus JE; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands., Otero ME; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands., Gostynski AH; Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands., Njoo MD; Department of Dermatology, Ziekenhuisgroep Twente, Almelo, Hengelo, The Netherlands., Ossenkoppele PM; Department of Dermatology, Ziekenhuisgroep Twente, Almelo, Hengelo, The Netherlands., Haeck IM; Department of Dermatology, Utrecht Medisch Centrum, Utrecht, The Netherlands., Hendricksen-Roelofzen JHJ; Department of Dermatology, Streekziekenhuis Koningin Beatrix, Winterswijk, The Netherlands., Körver JEM; Department of Dermatology, Amphia Ziekenhuis, Breda, The Netherlands., Dodemont SRP; Department of Dermatology, Catharina Ziekenhuis, Eindhoven, The Netherlands., Tupker RA; Department of Dermatology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands., Berends MAM; Department of Dermatology, Slingeland Ziekenhuis, Doetinchem, The Netherlands., Weppner-Parren LMJT; Department of Dermatology, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, The Netherlands., Keijsers RRMC; Department of Dermatology, Zuyderland Medisch Centrum, Sittard-Geleen, Heerlen, The Netherlands., Oostveen AM; Department of Dermatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands., Peters B; Department of Dermatology, Ziekenhuis Rijnstate, Arnhem, The Netherlands., Mommers R; Department of Dermatology, Anna Ziekenhuis, Geldrop, The Netherlands., van Doorn MBA; Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands., Tjioe M; Department of Dermatology, Bravis, Bergen op Zoom, The Netherlands/dermaTeam, Middelburg, The Netherlands., Veldkamp WR; Department of Dermatology, Ziekenhuis Gelderse Vallei, Ede, The Netherlands., Kuijpers ALA; Department of Dermatology, Máxima MC, Eindhoven, The Netherlands., Kleinpenning MM; Department of Dermatology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands., de Jong EMGJ; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands.; Radboud University, Nijmegen, The Netherlands., van den Reek JMPA; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands.

المصدر: American journal of clinical dermatology [Am J Clin Dermatol] 2024 Jul; Vol. 25 (4), pp. 685-688. Date of Electronic Publication: 2024 May 27.

نوع المنشور: Letter

بيانات الدورية: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100895290 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1888 (Electronic) Linking ISSN: 11750561 NLM ISO Abbreviation: Am J Clin Dermatol Subsets: MEDLINE

مواضيع طبية MeSH: Psoriasis*/drug therapy , Psoriasis*/immunology , Ustekinumab*/therapeutic use , Interleukin-23*/antagonists & inhibitors , Interleukin-23*/immunology , Dermatologic Agents*/therapeutic use , Drug Substitution*, Humans ; Treatment Outcome ; Female ; Male ; Middle Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Adult ; Severity of Illness Index ; Retrospective Studies ; Adalimumab/therapeutic use

المؤلفون: Spekhorst LS; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands., de Graaf M; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands., Zuithoff NPA; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., van den Reek JMPA; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands., Kamsteeg M; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands., Boesjes CM; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands., Romeijn GLE; Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands., Loman L; Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands., Haeck I; Department of Dermatology, Reinier de Graaf Gasthuis, Delft, the Netherlands., Oosting AJ; Department of Dermatology, Spaarnegasthuis, Haarlem, the Netherlands., de Boer-Brand A; Department of Dermatology, St Antonius Ziekenhuis, Nieuwegein, the Netherlands., Touwslager WRH; Department of Dermatology, Catharina Ziekenhuis, Eindhoven, the Netherlands., Flinterman A; Department of Dermatology, Diakonessenhuis, Utrecht, the Netherlands., van Lynden-van Nes AMT; Department of Dermatology, Meander Medisch Centrum, Amersfoort, the Netherlands., Gostynski AH; Department of Dermatology, University Medical Center Maastricht, Maastricht, the Netherlands., de Bruin-Weller MS; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands., Schuttelaar ML; Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands.

المصدر: JAMA dermatology [JAMA Dermatol] 2022 Sep 01; Vol. 158 (9), pp. 1048-1056.

نوع المنشور: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE

مواضيع طبية MeSH: Dermatitis, Atopic*/drug therapy, Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Humanized ; Cohort Studies ; Double-Blind Method ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Prospective Studies ; Registries ; Severity of Illness Index ; Treatment Outcome